Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24977966 | 0.81 | SMN1; SMN2 (0.42) | MAPTTDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24978513 | 0.75 | — | — | |
| SCHEMBL24978159 | 0.74 | — | — | |
| SCHEMBL24977964 | 0.73 | — | — | |
| SCHEMBL24871951 | 0.71 | KDM4E (0.33) | — | |
| SCHEMBL24871633 | 0.70 | KDM4E (0.33) | — | |
| SCHEMBL24978541 | 0.69 | SMN1; SMN2 (0.39) | MAPTTDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24978263 | 0.67 | — | — | |
| SCHEMBL22019708 | 0.67 | SMN1; SMN2 (0.46) | MAPTTDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24977994 | 0.64 | SMN1; SMN2 (0.41) | MAPTTDP1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPT 2020/4885TDP1 1532/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.